Research ExplorerPublicationsDNA hypermethylation as a predictor of PSA recurrence in pat...

DNA hypermethylation as a predictor of PSA recurrence in patients with low- and intermediate-grade prostate cancer

Standard

DNA hypermethylation as a predictor of PSA recurrence in patients with low- and intermediate-grade prostate cancer. / Moritz, Rudolf; Ellinger, Jörg; Nuhn, Philipp; Haese, Alexander; Müller, Stefan C; Graefen, Markus; Schlomm, Thorsten; Bastian, Patrick J.

In: ANTICANCER RES, Vol. 33, No. 12, 01.12.2013, p. 5249-54.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Moritz, R, Ellinger, J, Nuhn, P, Haese, A, Müller, SC, Graefen, M, Schlomm, T & Bastian, PJ 2013, 'DNA hypermethylation as a predictor of PSA recurrence in patients with low- and intermediate-grade prostate cancer', ANTICANCER RES, vol. 33, no. 12, pp. 5249-54.

APA

Moritz, R., Ellinger, J., Nuhn, P., Haese, A., Müller, S. C., Graefen, M., Schlomm, T., & Bastian, P. J. (2013). DNA hypermethylation as a predictor of PSA recurrence in patients with low- and intermediate-grade prostate cancer. ANTICANCER RES, 33(12), 5249-54.

Vancouver

Moritz R, Ellinger J, Nuhn P, Haese A, Müller SC, Graefen M et al. DNA hypermethylation as a predictor of PSA recurrence in patients with low- and intermediate-grade prostate cancer. ANTICANCER RES. 2013 Dec 1;33(12):5249-54.

Bibtex

@article{c03f3ed2a9c54489964738faec9f4b97,
title = "DNA hypermethylation as a predictor of PSA recurrence in patients with low- and intermediate-grade prostate cancer",
abstract = "BACKGROUND: DNA CpG island hypermethylation causes gene silencing and is a common event in prostate carcinogenesis and progression. We investigated its role as a possible prognostic marker in patients with PCA Gleason score ≤7.PATIENTS AND METHODS: We used a quantitative, methylation-specific PCR to analyze methylation patterns at five gene loci (APC, GSTP1, PTGS2, RARbeta and TIG1) in 84 prostate cancer (PCA) tissues (Gleason Score ≤7). Methylation was correlated with established clinico-pathological parameters (preoperative PSA, pathological Gleason score, extraprostatic extension, seminal vesicle penetration, lymph node involvement, surgical margins and age) and PSA recurrence.RESULTS: DNA hypermethylation was frequently detected at APC (95.2%), GSTP1 (84.5%), PTGS2 (100%), RAR-beta (81.0%) and TIG1 (95.2%). DNA hypermethylation was correlated with Gleason Score (p=0.027; PTGS2) and lymph node involvement (p=0.024; RARbeta). High methylation levels at RARbeta (p=0.023) was a significant predictor of PSA recurrence following radical prostatectomy.CONCLUSION: The analysis of DNA hypermethylation provides prognostic information in prognosis of low- and intermediate-grade PCA.",
keywords = "CpG Islands, DNA Methylation, Humans, Male, Middle Aged, Polymerase Chain Reaction, Prostate-Specific Antigen, Prostatic Neoplasms",
author = "Rudolf Moritz and J{\"o}rg Ellinger and Philipp Nuhn and Alexander Haese and M{\"u}ller, {Stefan C} and Markus Graefen and Thorsten Schlomm and Bastian, {Patrick J}",
year = "2013",
month = dec,
day = "1",
language = "English",
volume = "33",
pages = "5249--54",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

RIS

TY - JOUR

T1 - DNA hypermethylation as a predictor of PSA recurrence in patients with low- and intermediate-grade prostate cancer

AU - Moritz, Rudolf

AU - Ellinger, Jörg

AU - Nuhn, Philipp

AU - Haese, Alexander

AU - Müller, Stefan C

AU - Graefen, Markus

AU - Schlomm, Thorsten

AU - Bastian, Patrick J

PY - 2013/12/1

Y1 - 2013/12/1

N2 - BACKGROUND: DNA CpG island hypermethylation causes gene silencing and is a common event in prostate carcinogenesis and progression. We investigated its role as a possible prognostic marker in patients with PCA Gleason score ≤7.PATIENTS AND METHODS: We used a quantitative, methylation-specific PCR to analyze methylation patterns at five gene loci (APC, GSTP1, PTGS2, RARbeta and TIG1) in 84 prostate cancer (PCA) tissues (Gleason Score ≤7). Methylation was correlated with established clinico-pathological parameters (preoperative PSA, pathological Gleason score, extraprostatic extension, seminal vesicle penetration, lymph node involvement, surgical margins and age) and PSA recurrence.RESULTS: DNA hypermethylation was frequently detected at APC (95.2%), GSTP1 (84.5%), PTGS2 (100%), RAR-beta (81.0%) and TIG1 (95.2%). DNA hypermethylation was correlated with Gleason Score (p=0.027; PTGS2) and lymph node involvement (p=0.024; RARbeta). High methylation levels at RARbeta (p=0.023) was a significant predictor of PSA recurrence following radical prostatectomy.CONCLUSION: The analysis of DNA hypermethylation provides prognostic information in prognosis of low- and intermediate-grade PCA.

AB - BACKGROUND: DNA CpG island hypermethylation causes gene silencing and is a common event in prostate carcinogenesis and progression. We investigated its role as a possible prognostic marker in patients with PCA Gleason score ≤7.PATIENTS AND METHODS: We used a quantitative, methylation-specific PCR to analyze methylation patterns at five gene loci (APC, GSTP1, PTGS2, RARbeta and TIG1) in 84 prostate cancer (PCA) tissues (Gleason Score ≤7). Methylation was correlated with established clinico-pathological parameters (preoperative PSA, pathological Gleason score, extraprostatic extension, seminal vesicle penetration, lymph node involvement, surgical margins and age) and PSA recurrence.RESULTS: DNA hypermethylation was frequently detected at APC (95.2%), GSTP1 (84.5%), PTGS2 (100%), RAR-beta (81.0%) and TIG1 (95.2%). DNA hypermethylation was correlated with Gleason Score (p=0.027; PTGS2) and lymph node involvement (p=0.024; RARbeta). High methylation levels at RARbeta (p=0.023) was a significant predictor of PSA recurrence following radical prostatectomy.CONCLUSION: The analysis of DNA hypermethylation provides prognostic information in prognosis of low- and intermediate-grade PCA.

KW - CpG Islands

KW - DNA Methylation

KW - Humans

KW - Male

KW - Middle Aged

KW - Polymerase Chain Reaction

KW - Prostate-Specific Antigen

KW - Prostatic Neoplasms

M3 - SCORING: Journal article

C2 - 24324057

VL - 33

SP - 5249

EP - 5254

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 12

ER -